Chris Shibutani
Stock Analyst at Goldman Sachs
(3.40)
# 917
Out of 4,754 analysts
96
Total ratings
53.06%
Success rate
3.3%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $34.11 | -6.19% | 7 | Feb 14, 2025 | |
| PCVX Vaxcyte | Initiates: Buy | $135 | $72.10 | +87.24% | 1 | Dec 20, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $111.56 | +22.80% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $15.48 | +113.18% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $310.03 | -2.59% | 4 | Nov 1, 2024 | |
| ERAS Erasca | Maintains: Buy | $3 → $3.5 | $1.28 | +173.44% | 6 | Oct 25, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $33.86 | +50.62% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $167.28 | -7.34% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $3.00 | +33.33% | 8 | Jul 12, 2024 | |
| OGN Organon & Co. | Maintains: Neutral | $18 → $20 | $14.35 | +39.37% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $929.72 | -22.23% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $21.24 | +22.41% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $114.48 | +33.65% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $211.48 | -18.20% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.80 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $1.25 | $0.75 | +65.80% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $59.87 | +15.25% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $17.79 | -26.93% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $38.34 | -40.01% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.44 | +3,372.22% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $30.17 | +72.36% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $26.25 | +128.57% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $11.33 | +58.87% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.90 | +794.74% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.16 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.08 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.35 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.51 | - | 3 | May 2, 2017 |
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $34.11
Upside: -6.19%
Vaxcyte
Dec 20, 2024
Initiates: Buy
Price Target: $135
Current: $72.10
Upside: +87.24%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $111.56
Upside: +22.80%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $15.48
Upside: +113.18%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $310.03
Upside: -2.59%
Erasca
Oct 25, 2024
Maintains: Buy
Price Target: $3 → $3.5
Current: $1.28
Upside: +173.44%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $33.86
Upside: +50.62%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $167.28
Upside: -7.34%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $3.00
Upside: +33.33%
Organon & Co.
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $14.35
Upside: +39.37%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $929.72
Upside: -22.23%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $21.24
Upside: +22.41%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $114.48
Upside: +33.65%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $211.48
Upside: -18.20%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.80
Upside: -
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.75
Upside: +65.80%
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $59.87
Upside: +15.25%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $17.79
Upside: -26.93%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $38.34
Upside: -40.01%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.44
Upside: +3,372.22%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $30.17
Upside: +72.36%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $26.25
Upside: +128.57%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.33
Upside: +58.87%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $1.90
Upside: +794.74%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.16
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.08
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.35
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $13.51
Upside: -